Ionis says FDA approves ZANVASTRO for Alexander disease
Ionis said the FDA approved ZANVASTRO (zilganersen) as the first disease-modifying treatment for Alexander disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
US FDA approves Ionis therapy Zanvastro for rare brain disorder
The U.S. FDA approved Ionis Pharmaceuticals’ zilganersen (Zanvastro) to treat a rare genetic disorder affecting the brain’s white matter, with use for adults and pediatric patients.
IONS: FDA Approves TRYNGOLZA
IONS' TRYNGOLZA approved by FDA to reduce triglycerides and risk of acute pancreatitis in patients with severe hypertriglyceridemia
IONS: FDA Approves Treatment
FDA approves Ionis' treatment to reduce acute pancreatitis risk in adults with severe hypertriglyceridemia